As many as 60% of BrCA patients receiving radiation are known to develop fatigue with about 30% suffering persistent fatigue several months to years after treatment completion. The nuclear factor-kB (NF-kB) pathway has emerged as having an important role not only in cancer treatment resistance, but also in the development of fatigue. This project will explore the effectiveness of Meriva, a formulation of the natural product curcumin already shown to target NF-kB, to attenuate fatigue in women after treatment for breast cancer. For more information on this study please click here. This study is no longer recruiting.